These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19684517)

  • 1. FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
    Sanz M; Burnett A; Lo-Coco F; Löwenberg B
    Curr Opin Oncol; 2009 Nov; 21(6):594-600. PubMed ID: 19684517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 mutations: biology and treatment.
    Small D
    Hematology Am Soc Hematol Educ Program; 2006; ():178-84. PubMed ID: 17124058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
    Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
    Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
    Swords R; Freeman C; Giles F
    Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
    Knapper S; Mills KI; Gilkes AF; Austin SJ; Walsh V; Burnett AK
    Blood; 2006 Nov; 108(10):3494-503. PubMed ID: 16868253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
    Fathi AT; Chabner BA
    Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
    Tickenbrock L; Müller-Tidow C; Berdel WE; Serve H
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):153-65. PubMed ID: 16503833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
    Heidel F; Solem FK; Breitenbuecher F; Lipka DB; Kasper S; Thiede MH; Brandts C; Serve H; Roesel J; Giles F; Feldman E; Ehninger G; Schiller GJ; Nimer S; Stone RM; Wang Y; Kindler T; Cohen PS; Huber C; Fischer T
    Blood; 2006 Jan; 107(1):293-300. PubMed ID: 16150941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
    Knapper S; Burnett AK; Littlewood T; Kell WJ; Agrawal S; Chopra R; Clark R; Levis MJ; Small D
    Blood; 2006 Nov; 108(10):3262-70. PubMed ID: 16857985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
    Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
    Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.
    Kayser S; Levis MJ
    Leuk Lymphoma; 2014 Feb; 55(2):243-55. PubMed ID: 23631653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can FLT3 inhibitors overcome resistance in AML?
    Tam WF; Gary Gilliland D
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.